Today: 20 May 2026
Browse Category

NASDAQ:INTS 30 October 2025 - 31 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Shares of Intensity Therapeutics closed at $1.32 on Oct. 30, surging nearly 395% intraday after Phase 1/2 trial data for INT230-6 showed a 75% disease-control rate in metastatic cancer. Over a billion shares traded, dwarfing the usual volume. After-hours, the price fell to around $0.90. The company’s market cap remains under $65 million.
31 October 2025
··
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 30.10.2025

US stocks fell Oct. 30, with the S&P 500 down 0.99% and Nasdaq off 1.57%. Oracle shares dropped 6.8% to $256.28 despite analysts raising price targets and maintaining buy ratings. Liberty Latin America slid about 6% in a month, closing near $7.77, well below its $10.63 fair value estimate. Intensity Therapeutics surged nearly 400%, while CERO plunged almost 95%.
30 October 2025
·······

Stock Market Today

  • Rainbow Children's Medicare (NSE:RAINBOW) Attracts Investors with Consistent Profit Growth
    May 20, 2026, 2:58 AM EDT. Rainbow Children's Medicare (NSE:RAINBOW) has drawn investor attention due to its consistent earnings per share (EPS) growth of 14% annually over the past three years. The company maintained stable earnings before interest and tax (EBIT) margins while growing revenue by 8.5% to ₹16 billion, signalling strong operational performance. Insiders hold 52% ownership, worth around ₹71 billion, indicating aligned interests with shareholders and confidence in long-term value creation. This contrasts with loss-making companies reliant on external capital, showcasing Rainbow Children's Medicare as a profitable, fundamentally sound investment opportunity in the Indian healthcare sector.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop